Update shared on 22 Nov 2025
Fair value Decreased 1.51%The analyst price target for Trulieve Cannabis has decreased slightly from $19.16 to $18.87. Analysts cite modest adjustments to profit margin expectations and valuation metrics as reasons for the change.
Analyst Commentary
Analyst sentiment on Trulieve Cannabis has shifted modestly in recent updates, with experts weighing the company’s performance, growth outlook, and potential risks that may impact future valuation. Below, key bullish and bearish takeaways summarize the current perspectives driving the revised price target.
Bullish Takeaways- Bullish analysts note Trulieve has demonstrated resilience in its operational execution, maintaining steady revenues despite a challenging industry environment.
- The company’s disciplined cost control and consistent focus on improving profit margins have contributed positively to confidence in its near-term profitability.
- There is optimism around Trulieve’s strategic market positioning and its capacity to continue expansion efforts within regulated cannabis markets.
- Some projections anticipate incremental growth opportunities as state-level legalization progresses. This is seen as offering long-term upside potential for the company’s business model.
- Bearish analysts remain cautious about the slower than expected pace of margin expansion, which may constrain near-term valuation improvement.
- Regulatory uncertainty and evolving competitive dynamics are cited as key headwinds that could pressure future earnings and market share.
- Persistently high operating expenses within the sector, combined with thinner expected profit margins, add risk to achieving aggressive growth targets.
What's in the News
- Trulieve Cannabis has provided financial guidance for Q4 2025, anticipating low single-digit sequential revenue growth.
- The company launched five new 10 milligram flavors of Onward and Upward THC-infused beverages, with products available online and at retail in Florida and Illinois.
- Trulieve expanded its retail footprint with new dispensary openings in Bisbee, Arizona, and Cincinnati, Ohio, increasing its presence in both states.
- Jan Reese has been appointed as Trulieve Cannabis' new Chief Financial Officer, bringing over two decades of executive finance experience. He will assume his responsibilities in September 2025.
Valuation Changes
- Consensus Analyst Price Target has decreased modestly, moving from $19.16 to $18.87.
- Discount Rate remains unchanged at 6.45%, indicating stable risk assumptions.
- Revenue Growth expectations are largely steady, with a negligible increase from 1.99% to 1.99%.
- Net Profit Margin has risen significantly, climbing from 1.21% to 2.85%.
- Future P/E ratio has fallen sharply, dropping from 212.0x to 75.3x, which reflects lower expected future earnings multiples.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.